Please login to the form below
Vizimpro
This page shows the latest Vizimpro news and features for those working in and with pharma, biotech and healthcare.
Tagrisso tops rival drugs on survival in first-line lung cancer
Takes fight to Pfizer's Vizimpro. AstraZeneca has the improvement in overall survival (OS) it needed for lung cancer therapy Tagrisso (osimertinib), as it tries to double down on its use ... NICE also judged that the drug would not eligible for inclusion
Latest news
-
AstraZenca to appeal NICE rejection of Tagrisso
The decision not to recommend Tagrisso coincided with NICE’s recommendation of Pfizer’s Vizimpro (dacomitinib) in the same patient population. ... However, NICE did acknowledge that Vizimpro had a higher incidence of side effects, so a lower dose
-
Pfizer’s Talzenna cleared for breast cancer in Europe
Daurismo (glasdegib) for acute myeloid leukaemia, and Vizimpro (dacomitinib) for locally advanced or metastatic EGFR-positive non-small cell lung cancer (NSCLC).
-
Pfizer poaches cancer R&D head Jeff Settleman from Calico
That includes Xalkori follow-up Lorbrena (lorlatinib) for ALK-positive non-small cell lung cancer (NSCLC), PARP inhibitor Talzenna (talazoparib) for breast cancer, Daurismo (glasdegib) for acute myeloid leukaemia, and Vizimpro
-
Solid Q1 results lift Pfizer as it waits for pipeline boost
That will come on the back of product launches like tafamidis in rare disease transthyretin amyloid cardiomyopathy, a trio of recently-approved cancer drugs including Vizimpro (dacomitinib), a rival to
-
Pfizer gets EU nod for Tagrisso rival Vizimpro
Five year survival still only 12%. Pfizer’s Vizimpro, a drug that could challenge AstraZeneca’s fast-growing Tagrisso in lung cancer, has been approved for marketing by the European Commission. ... Vizimpro (dacomitinib) has been approved in the EU
More from news
Approximately 5 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Integrating patient reported outcomes into clinical trials
In its 2019 reviews of Pfizer’s Vizimpro and Takeda’s Adcetris, NICE noted that EQ-5D “may not be sensitive to skin-related diseases” and may fail to fully capture
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- First trial of a vaccine against Alzheimer’s launches
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Lucid Group: Orange the World
- First trial of a vaccine against Alzheimer’s launches
- New COVID variant causing concern
- PMEA 2021: A Celebration of Excellence in Patient Engagement
- From Academics to Entrepreneurship: How Tech is Revolutionizing the Diagnostics Landscape
- Impetus Digital wins Canada’s Most Admired Corporate Cultures Awards 2021
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Biogen’s Aduhelm unlikely to get approval in Europe
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- The pandemic preparedness paradox
- First trial of a vaccine against Alzheimer’s launches
- Good NICE news for Pfizer, but Dendreon drug rejected
PMHub
W2O Group
W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
